BAFF/TNFSF13B 蛋白, Human (HEK293, Fc)

BAFF/TNFSF13B, is the B cell-activating cytokine belonging to the tumor necrosis factor family. BAFF is involved in cancer immunity and is mainly expressed in myeloid cells. Its overexpression can lead to autoimmune diseases such as systemic lupus erythematosus (SLE). In addition, BAFF is also involved in adipogenesis, atherosclerosis, neuroinflammatory process and ischemia/reperfusion (I/R) injury ^[1]. Human BAFF protein has two glycosylated domains and one transmembrane domain (48-68 a.a.), and can be cleaved into membrane-type peptide fragments and soluble peptide fragments. BAFF/TNFSF13B Protein, Human (HEK293, Fc) is the extracullar part of BAFF protein (A134-L285), produced in HEK293 cells with N-terminal hFc-tag.

B细胞激活因子（BAFF）属于肿瘤坏死因子家族，也称为B淋巴细胞刺激因子（BLyS），树突状细胞衍生的TNF样分子，以及TNF和APOL相关的白细胞表达配体1（TALL-1） ）。BAFF是自身反应性B细胞的替代细胞，主要表达于骨髓细胞系。BAFF 的表达水平对于免疫很重要，而过度的 BAFF 信号传导会导致自身免疫。例如，BAFF 通常在系统性红斑狼疮 (SLE) 中过度表达。此外，BAFF 似乎还参与脂肪生成、动脉粥样硬化、神经炎症过程和缺血再灌注 (I/R) 损伤^[1]。DeltaBAFF 是 BAFF 的保守可变剪接亚型，缺少编码 A-A1 环的 57 nt。DeltaBAFF 与 BAFF 在许多小鼠和人类骨髓细胞中共表达。小鼠中的 DeltaBAFF 通过质膜上的蛋白水解作用而低效释放，并与异源多聚体中的 BAFF 结合，从而降低 BAFF 的生物活性和释放。小鼠BAFF蛋白具有2个糖基化结构域和1个跨膜结构域（48-68个氨基酸），可裂解成膜型肽片段和可溶性肽片段。而且，人和小鼠的蛋白质序列存在差异，相似度高达68.23%^[2]。BAFF 还涉及癌症免疫。BAFF上调多种B细胞共刺激分子；体外增强 IL-12a 表达并增强 B 细胞抗原呈递给 CD4⁺ Th 细胞。它还通过增加 T 细胞活化和 TH1 极化、增强促炎白细胞运输趋化因子 CCR6 的表达以及促进记忆表型来调节 T 细胞功能，从而增强抗肿瘤免疫力。BAFF 具有独特的免疫调节功能，可促进脾脏和肿瘤微环境 (TME) 中 CD4+Foxp3+ Tregs 的扩增^[3]。

BAFF (human; 10 μg/kg; i.v.; single dose) resulted in a decrease in signaling through the non-canonical NF-κB pathway and a reduction in B-cells in the spleen in mice^[4].

Measured by its binding ability in a functional ELISA. When Recombinant BCMA Protein (HY-P70827) is immobilized at 2 µg/mL (100 µL/well) can bind Recombinant Human BAFF. The ED₅₀ for this effect is 9.159-13.72 ng/mL.

Human

HEK293

N-hFc

Q9Y275-1 (A134-L285)

10673  [NCBI]

AVQGPEETVTQDCLQLIADSETPTIQKGSYTFVPWLLSFKRGSALEEKENKILVKETGYFFIYGQVLYTDKTYAMGHLIQRKKVHVFGDELSLVTLFRCIQNMPETLPNNSCYSAGIAKLEEGDELQLAIPRENAQISLDGDVTFFGALKLL

Approximately 45-54.0 kDa due to the glycosylation.

Greater than 95% as determined by reducing SDS-PAGE.

无菌粉末

Lyophilized from a 0.2 μm filtered solution of PBS, pH 7.4 or 20 mM Tris-HCl, 15%Trehalose, 4% Dextran-70, 0.05% Tween 80, pH 8.5 or PBS, pH 7.4, 8% trehalose.

<1 EU/μg, determined by LAL method.

It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH₂O.

Stored at -20°C for 2 years. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Room temperature in continental US; may vary elsewhere.

• [1]. Möckel T, et al. B cell activating factor (BAFF): Structure, functions, autoimmunity and clinical implications in Systemic Lupus Erythematosus (SLE). Autoimmun Rev. 2021 Feb;20(2):102736.  [Content Brief]

  [2]. Gavin AL, et al. DeltaBAFF, an alternate splice isoform that regulates receptor binding and biopresentation of the B cell survival cytokine, BAFF. J Biol Chem. 2003 Oct 3;278(40):38220-8.  [Content Brief]

  [3]. Yarchoan M, et al. Effects of B cell-activating factor on tumor immunity. JCI Insight. 2020 May 21;5(10):e136417.  [Content Brief]

  [4]. Manetta J, et al. Generation and characterization of tabalumab, a human monoclonal antibody that neutralizes both soluble and membrane-bound B-cell activating factor. J Inflamm Res. 2014 Aug 20;7:121-31.  [Content Brief]